This company has shut down. Elevation Oncology is no longer operating — its last tracked round was a Post-IPO Equity in 2023.
Explore the Startup GraveyardElevation Oncology is a clinical-stage biopharmaceutical company focused on the development of precision medicines for patients.
Elevation Oncology has raised $50.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in June 2023.
Elevation Oncology's investors include Cormorant Asset Management, Vivo Capital, Janus Henderson Investors, Samsara BioCapital, Qiming Venture Partners USA.
Elevation Oncology is headquartered in New York, United States.
Elevation Oncology is a clinical-stage biopharmaceutical company focused on the development of precision medicines for patients.
Elevation Oncology is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Elevation Oncology — Funding & Investors." VCBacked, June 8, 2023, https://www.vcbacked.co/company/elevation-oncology. Accessed July 19, 2026.
VCBacked. (2023). Elevation Oncology — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/elevation-oncology
{{cite web |title=Elevation Oncology — Funding & Investors |url=https://www.vcbacked.co/company/elevation-oncology |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated